Symbiotec Pharmalab Peer Comparison

NSE: SYMBIOTEC | BSE: 544889

₹1,198.00

₹21.25 (1.81%)

As on 01-Oct-2026IST

Market cap

₹7,706 Cr

Revenue (TTM)

₹869 Cr

P/E Ratio

70.1

P/B Ratio

5.1

Div. Yield

0 %

Edit

	Symbiotec Pharmalab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	7,706	36,872	27,580	16,849	14,385
Revenue (₹ Cr)	869	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	109.90	1,018.97	497.77	603.02	270.18
Net Margin (%)	12.60	10.47	20.72	22.63	23.29
RoE (%)	11.22	21.30	28.49	19.61	14.45
Price to Earnings	70.12	36.46	55.41	27.94	52.24
Price-To-Book	5.14	7.05	13.64	4.83	6.94

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Symbiotec Pharmalab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	869.15	9,203.54	2,022.99	2,551.83	1,054.89
Total Income	872.26	9,335.01	2,053.15	2,612.24	1,107.25
Total Expenditure	630.48	7,457.80	1,448.49	1,754.55	686.95
EBITDA	238.67	1,745.74	574.50	797.28	367.94
Depreciation	53.28	415.05	91.74	75.36	74.46
EBIT	185.39	1,330.70	482.76	721.93	293.48
Interest	26.14	143.67	23.95	5.37	0.82
Other Income	3.11	131.47	30.17	60.41	52.36
Exceptional Items	-8.99	-31.35	--	-25.66	-3.28
Profit before Tax	153.36	1,287.14	488.98	751.31	344.65
Provision for Tax	43.46	345.87	124.98	186.83	85.42
Profit after Tax	109.90	941.27	364.00	564.48	259.23

Liabilities (₹ Cr)

	Symbiotec Pharmalab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	1,149.73	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	-0.14	26.64	--	--	-1.92
Non-Current Liabilities	103.64	584.19	345.47	142.73	47.58
Current Liabilities	527.57	3,912.24	710.20	682.24	169.08
Total Liabilities	1,780.79	9,514.48	2,930.14	4,157.10	2,231.79

Assets (₹ Cr)

	Symbiotec Pharmalab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	1,295.25	3,861.01	1,447.01	1,333.54	981.68
Current Assets	485.54	5,612.10	1,483.13	2,823.56	1,250.11
Total Assets	1,780.79	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	387.91	1,204.08	196.61	0.00	0.00
Net Current Assets	-42.02	1,699.86	772.93	2,141.33	1,081.03
Contingent Liabilities	--	258.92	13.18	4.82	3.76

Cashflow (₹ Cr)

	Symbiotec Pharmalab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	174.59	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-226.93	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	35.99	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	-16.35	93.92	-56.08	-69.08	11.28

Ratios

Profitability Ratios

	Symbiotec Pharmalab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	12.41	25.25	27.50	24.61	18.04
ROE (%)	11.22	20.09	21.43	18.41	13.54
ROA (%)	6.54	10.70	14.25	14.27	12.15
EBIT Margin (%)	27.82	20.40	29.89	33.61	39.84
Net Margin (%)	12.60	10.08	17.73	21.61	23.41
Cash Profit Margin (%)	18.57	14.44	22.53	24.81	31.63

Growth Ratios

	Symbiotec Pharmalab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	15.65	16.56	36.98	6.91	-12.10
EBIT Growth (%)	16.72	21.77	75.89	19.60	-23.76
Net Profit Growth (%)	13.55	33.05	39.94	16.24	-30.25
EPS Growth (%)	-1.03	35.59	39.94	16.05	-29.80
Book Value Growth (%)	41.75	11.36	22.95	18.43	11.27

Valuation Ratios

	Symbiotec Pharmalab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	0.00	32.73	42.34	21.18	40.73
Price / Book Value	0.00	6.13	8.23	3.60	5.27
Dividend Yield (%)	--	0.23	0.28	0.51	0.74
EV/EBITDA	1.61	16.68	25.23	13.94	25.25
Market Cap (₹ Cr)	0.00	30,257.56	15,412.11	11,956.86	10,627.92

Solvency Ratios

	Symbiotec Pharmalab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.34	0.24	0.10	0.00	0.00
Short term debt to equity ratio	0.25	0.16	--	--	--
Current Ratio	0.92	1.43	2.09	4.14	7.39
Quick Ratio	0.47	0.82	1.37	3.12	5.46
Interest Coverage	6.87	9.96	21.42	140.86	419.57

Operating Efficiency Ratios

	Symbiotec Pharmalab	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	22.73	27.84	26.76	42.05	43.63
Asset Turnover	0.52	1.07	0.79	0.65	0.49
Receivable days	77.53	88.68	77.32	144.58	169.86
Inventory Days	103.51	84.11	80.83	96.67	97.92
Payable days	131.22	176.65	125.94	135.45	159.68
Cash Conversion Cycle	49.82	-3.86	32.22	105.80	108.11